Who owns KINNATE BIOPHARMA INC?
- Ticker: KNTE
- CUSIP Number: 49705r105
Tip: Access positions for across all investors
Analyze quarterly positions in Kinnate Biopharma with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Kinnate Biopharma stock
Who bought or sold KINNATE BIOPHARMA INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | ||
|---|---|---|---|---|---|---|
| Foresite Capital Management IV | 9.7M | $301M | 0% | Mar 2021 | ||
| OrbiMed Advisors | 3.8M | $153M | 100% | Dec 2020 | ||
| RA Capital Management | 3.6M | $143M | 100% | Dec 2020 | ||
| Vida Ventures Advisors | 2.7M | $86M | 0% | Mar 2021 | ||
| FMR | 2.1M | $65M | -13% | Mar 2021 | ||
| Viking Global Investors | 1.9M | $75M | 100% | Dec 2020 | ||
| VR Adviser | 1.5M | $46M | 0% | Mar 2021 | ||
| Citadel Advisors | 1.3M | $44M | 0% | Mar 2021 | ||
| Vanguard Group | 1.3M | $41M | 53% | Mar 2021 | ||
| BlackRock | 1.2M | $38M | 291% | Mar 2021 | ||
| Boxer Capital | 1.1M | $42M | 100% | Dec 2020 | ||
Setup an alertWant to be notified whenever an investor makes a significant change to their holdings of Kinnate Biopharma? |
||||||
| Foresite Capital Management V | 875k | $27M | 0% | Mar 2021 | ||
| Henderson Group | 800k | $24M | -1% | Mar 2021 | ||
| T. Rowe Price Associates | 649k | $20M | 0% | Mar 2021 | ||
| Logos Global Management | 570k | $23M | 100% | Dec 2020 | ||
| Harvard Management Company | 498k | $16M | 0% | Mar 2021 | ||
| Deerfield Management Company | 345k | $14M | 100% | Dec 2020 | ||
| Partner Fund Management | 342k | $14M | 100% | Dec 2020 | ||
| Rock Springs Capital Management | 326k | $10M | 1% | Mar 2021 | ||
| Federated Investors | 308k | $9.6M | 23% | Mar 2021 | ||
| Novo A/S | 300k | $9.3M | 0% | Mar 2021 | ||
| Woodline Partners | 286k | $8.9M | 4% | Mar 2021 | ||
| Farallon Capital Management | 250k | $7.8M | 0% | Mar 2021 | ||
| Geode Capital Management | 239k | $7.4M | 709% | Mar 2021 | ||
| State Street Corporation | 183k | $5.7M | 100% | Mar 2021 | ||
| Franklin Resources | 175k | $5.5M | 0% | Mar 2021 | ||
| American Century Companies | 174k | $5.4M | 2331% | Mar 2021 | ||
| Northern Trust | 146k | $4.5M | 100% | Mar 2021 | ||
| Artal Group | 125k | $3.9M | 0% | Mar 2021 | ||
| Soleus Capital Management | 109k | $3.4M | 100% | Mar 2021 | ||
| Victory Capital Management | 102k | $3.2M | -4% | Mar 2021 | ||
| Millennium Management | 90k | $3.6M | 100% | Dec 2020 | ||
| Charles Schwab Investment Management | 89k | $2.8M | 100% | Mar 2021 | ||
| DAFNA Capital Management | 53k | $1.6M | -22% | Mar 2021 | ||
| Nuveen Asset Management | 49k | $1.5M | 100% | Mar 2021 | ||
| TD Asset Management | 45k | $1.4M | 17% | Mar 2021 | ||
| Tudor Investment Corporation | 40k | $1.6M | 100% | Dec 2020 | ||
| Bank of New York Mellon | 36k | $1.1M | 100% | Mar 2021 | ||
| Bank of America Corporation | 27k | $848k | 100% | Mar 2021 | ||
| Deutsche Bank Aktiengesellschaft | 27k | $842k | 100% | Mar 2021 | ||
| EcoR1 Capital | 25k | $779k | 0% | Mar 2021 | ||
| California State Teachers Retirement System | 20k | $635k | 100% | Mar 2021 | ||
| Goldman Sachs Group | 18k | $554k | -71% | Mar 2021 | ||
| Ensign Peak Advisors | 15k | $467k | 0% | Mar 2021 | ||
| Parkwood | 13k | $411k | 100% | Mar 2021 | ||
| Rhumbline Advisers | 12k | $364k | 100% | Mar 2021 | ||
| American International | 7.9k | $245k | 100% | Mar 2021 | ||
| Chicago Partners Investment | 7.6k | $204k | 100% | Mar 2021 | ||
| Manufacturers Life Insurance Company | 7.6k | $236k | 100% | Mar 2021 | ||
| New York State Common Retirement Fund | 7.3k | $227k | 100% | Mar 2021 | ||
| MetLife Investment Advisors | 6.4k | $200k | 100% | Mar 2021 | ||
| Jpmorgan Chase & Co | 5.1k | $158k | 100% | Mar 2021 | ||
| Wells Fargo & Company | 4.2k | $131k | 100% | Mar 2021 | ||
| OTR - Nominee Name for The State Teachers Retirement Board of Ohio | 3.3k | $102k | 100% | Mar 2021 | ||
| Ikarian Capital | 2.0k | $62k | 0% | Mar 2021 | ||
| Royal Bank of Canada | 1.8k | $56k | 258% | Mar 2021 | ||
| Legal & General Group | 1.4k | $42k | 100% | Mar 2021 | ||
| Summit Investment Advisors | 1.1k | $34k | 100% | Mar 2021 | ||
| Citigroup | 995.00 | $31k | -93% | Mar 2021 | ||
| UBS Group | 788.00 | $25k | -98% | Mar 2021 | ||
| Tower Research Capital | 650.00 | $20k | 100% | Mar 2021 | ||
| Bank Of Montreal | 419.00 | $13k | 100% | Mar 2021 | ||
| Metropolitan Life Insurance Company | 5.00 | $146.000000 | 100% | Mar 2021 | ||
Who sold out of Kinnate Biopharma?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Eventide Asset Management | Dec 2020 | 175k | $7.0M |
| Invesco | Dec 2020 | 167k | $6.7M |
| Pinz Capital Management | Dec 2020 | 26k | $1.0M |
| Norges Bank Investment Management | Dec 2020 | 25k | $995k |
| ExodusPoint Capital Management | Dec 2020 | 21k | $835k |
| SG Americas Securities | Dec 2020 | 13k | $533k |
| Tibra Equities Europe | Dec 2020 | 13k | $533k |
| Mirabella Financial Services | Dec 2020 | 10k | $412k |
| Qube Research & Technologies | Dec 2020 | 6.1k | $242k |
| Jane Street | Dec 2020 | 6.0k | $241k |
| Maven Securities | Dec 2020 | 6.0k | $237k |
| Wellington Management Company | Dec 2020 | 5.7k | $227k |
| Hrt Financial | Dec 2020 | 5.6k | $223k |
| S.A.C. Capital Advisors | Dec 2020 | 5.5k | $217k |
| Rockefeller Capital Management | Dec 2020 | 3.3k | $129k |
| Pathstone Family Office | Dec 2020 | 198.00 | $8.0k |